Watching Nivolumab's Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma episode artwork

EPISODE · Nov 14, 2016 · 7 MIN

Watching Nivolumab's Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma

from Journal of Clinical Oncology (JCO) Podcast

This podcast provides commentary on a large dataset describing the expected frequency, severity and kinetics of immune-related adverse events associated with nivolumab monotherapy and the expected use of corticosteroid supportive therapy together with observations relating to the associations between immune adverse events, corticosteroid use and efficacy.

Episode metadata supplied by the publisher feed · Published Nov 14, 2016

Embed this episode

NOW PLAYING

Watching Nivolumab's Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma

0:00 7:58

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Journal of Clinical Oncology (JCO) Podcast?

This episode is 7 minutes long.

When was this Journal of Clinical Oncology (JCO) Podcast episode published?

This episode was published on November 14, 2016.

Can I download this Journal of Clinical Oncology (JCO) Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!